Gossamer Bio (GOSS) Expected to Announce Quarterly Earnings on Wednesday

Gossamer Bio (NASDAQ:GOSS) is expected to be announcing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of ($3.9340) per share and revenue of $12.16 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Gossamer Bio Stock Down 9.0%

NASDAQ GOSS opened at $9.45 on Tuesday. Gossamer Bio has a 12 month low of $8.29 and a 12 month high of $309.60. The company has a 50-day moving average of $11.20 and a 200-day moving average of $41.95.

Analysts Set New Price Targets

GOSS has been the subject of a number of recent analyst reports. Wall Street Zen downgraded shares of Gossamer Bio from a “hold” rating to a “sell” rating in a report on Sunday, September 20th. Weiss Ratings upgraded shares of Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 9th. Chardan Capital reissued a “buy” rating on shares of Gossamer Bio in a research note on Monday, October 26th. HC Wainwright restated a “buy” rating on shares of Gossamer Bio in a report on Thursday, August 27th. Finally, Leerink Partners raised Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 target price on the stock in a research report on Tuesday, July 28th. Five research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $256.00.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. The company concentrates primarily on immunology, inflammation and pulmonary disorders.

Its lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways involving platelet-derived growth factor, colony-stimulating factor 1 and stem cell factor receptors. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.